PACINGCURE B.V.
Desconocido
NaV1.5-CARED: NaV1.5 regulation fine-tuning as a therapy for cardiac Conduction and Arrhythmic diseases at Risk of...
PACINGCURE B.V.
participó en un
HORIZON EUROPE
HORIZON-EIC-2022-PATHFINDERCHALLENGES-01
The voltage-gated sodium channel (Na-channel; NaV1.5) is a central component of cardiac electrogenesis. Its dysfunction can lead to ventricu...
2023-06-21 - 2028-09-30 | Financiado
2023-06-21 - 2028-09-30 | Financiado
TRACTION: Transcription Factor Gene Therapy for Bradyarrhythmias
PACINGCURE B.V.
tramitó un
HORIZON EUROPE
HORIZON-EIC-2022-TRANSITION-01
PacingCure has developed BradyTx-01: a novel gene therapy medicinal product (GTMP) to cure life-threatening cardiac pacing dysfunctions by r...
2022-11-21 - 2025-12-31 | Financiado
2022-11-21 - 2025-12-31 | Financiado
* No se disponen de datos de la empresa actual.